Appia Bio Inc, a developer of engineered allogeneic cell therapies from hematopoietic stem cells for cancer patients, has raised $52 million in Series A financing. 8VC led the round with participation from other investors that included Two Sigma Ventures, Sherpa Healthcare Partners and Freeflow Ventures.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: